1. Advanced Age and CV Risk: To Start or Not to Start a Statin in Older Patients?

2. Definition of Elderly

3. The Elderly and Vascular Disease

4. Tailoring Lipid-Lowering Therapy in the Elderly

5. Statins Highly Favorable Risk-Benefit Ratio

6. Highest Risk of Statin Toxicity

7. Polypharmacy and Drug-Drug Interactions

8. Statin Pharmacokinetics

9. Pitavastatin and Pravastatin: Less Likely to Interact With Common Medications in CV Care

10. Common Drug Interactions With Statins

11. PROSPER Study Design

12. PROSPER Primary Endpoint

13. Primary Prevention in the Elderly MI and Stroke Reduced With Statins

14. JUPITER and HOPE-3 Trials

15. STAREE STAtins for Reducing Events in the Elderly

16. Secondary Prevention

17. Secondary Prevention (cont)

18. CTT Meta-Analysis

19. Guideline Recommendations Statin Therapy in the Elderly (>75 Years)

20. SCORE Cardiovascular Disease Risk Estimation

21. REAL-CAD: Primary Endpoint CV Death/MI/Ischemic Stroke/Unstable Angina

22. Nonadherence Is a Risk Factor for CV Events

23. Reassuring the Patient About Statins

24. 2015 ACC Health Policy Statement Team Management

25. Conclusion

26. Abbreviations

27. Abbreviations (cont)